Obligate anaerobic Salmonella typhimurium strain YB1 treatment on xenograft tumor in immunocompetent mouse model

Yu,Bin; Shi,Lei; Zhang,Bao‑Zhong; Zhang,Ke; Peng,Xiao; Niu,Han‑Ben; Qu,Jun‑Le

doi:10.3892/ol.2015.3302

Obligate anaerobic Salmonella typhimurium strain YB1 treatment on xenograft tumor in immunocompetent mouse model

Authors:
- Bin Yu
- Lei Shi
- Bao‑Zhong Zhang
- Ke Zhang
- Xiao Peng
- Han‑Ben Niu
- Jun‑Le Qu
View Affiliations

Affiliations: Key Laboratory of Optoelectronic Devices and Systems of Ministry of Education and Guangdong Province, College of Optoelectronic Engineering, Shenzhen University, Shenzhen, Guangdong 518060, P.R. China, Department of Biochemistry, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, SAR, P.R. China, Department of Microbiology, The University of Hong Kong, Pokfulam, Hong Kong, SAR, P.R. China
Published online on: June 2, 2015 https://doi.org/10.3892/ol.2015.3302
Pages: 1069-1074

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present authors have previously reported a novel approach to genetically engineer Salmonella typhimurium for the medically important therapeutic strategy of using bacterial agents to target malignant tumors in a breast cancer tumor‑bearing nude mouse model. However, studying an immunocompromised mouse model for cancer therapy is insufficient, as certain crucial information about the influence of the immune system may be missing. In the present study, inoculation of the Salmonella strain, YB1, into a colon cancer tumor‑bearing immunocompetent mouse model was investigated. The present study determined the tumor targeting efficiency, antitumor potential, the effects of multiple treatments and the systemic toxicity. Intravenous inoculation of YB1 in BALB/c mice exhibited high antitumor effects and also greatly increased the tumor targeting ability and safety compared with the previously‑reported nude mouse model. In addition, repeated administration of YB1 further enhanced this effect. Furthermore, no marked toxicity was observed with YB1 treatment, while the VNP20009 and SL7207 strains demonstrated certain adverse effects. The findings of the present study indicate that the YB1 strain is effective and safe in targeting a colon cancer tumor in an immunocompetent mouse model.

View Figures

View References

1	Pawelek JM, Low KB and Bermudes D: Bacteria as tumour-targeting vectors. Lancet Oncol. 4:548–556. 2003. View Article : Google Scholar : PubMed/NCBI
2	Yazawa K, Fujimori M, Amano J, Kano Y and Taniguchi S: Bifidobacterium longum as a delivery system for cancer gene therapy: selective localization and growth in hypoxic tumors. Cancer Gene Ther. 7:269–274. 2000. View Article : Google Scholar : PubMed/NCBI
3	Yazawa K, Fujimori M and Nakamura T: Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors. Breast Cancer Res Treat. 66:165–170. 2001. View Article : Google Scholar : PubMed/NCBI
4	Taniguchi S, Fujimori M, Sasaki T, Tsutsui H, Shimatani Y, Seki K and Amano J: Targeting solid tumors with non-pathogenic obligate anaerobic bacteria. Cancer Sci. 101:1925–1932. 2010. View Article : Google Scholar : PubMed/NCBI
5	Theys J, Dubois L, Anlezark G, et al: Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo. Br J Cancer. 95:1212–1219. 2006. View Article : Google Scholar : PubMed/NCBI
6	Liu SC, Ahn GO, Kioi M, Dorie MJ, Patterson AV and Brown JM: Optimized clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104. Cancer Res. 68:7995–8003. 2008. View Article : Google Scholar : PubMed/NCBI
7	Low KB, Ittensohn M, Le T, et al: Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo. Nat Biotechnol. 17:37–41. 1999. View Article : Google Scholar : PubMed/NCBI
8	Zhao M, Yang M, Li XM, et al: Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci USA. 102:755–760. 2005. View Article : Google Scholar : PubMed/NCBI
9	Zhao M, Yang M, Ma H, et al: Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. Cancer Res. 66:7647–7652. 2006. View Article : Google Scholar : PubMed/NCBI
10	Yu B, Yang M, Shi L, et al: Explicit hypoxia targeting with tumor suppression by creating an ‘obligate’ anaerobic Salmonella typhimurium strain. Sci Rep. 2:4362012. View Article : Google Scholar : PubMed/NCBI
11	Bertout JA, Patel SA and Simon MC: The impact of O₂ availability on human cancer. Nat Rev Cancer. 8:967–975. 2008. View Article : Google Scholar : PubMed/NCBI
12	Hill RP, Marie-Egyptienne DT and Hedley DW: Cancer stem cells, hypoxia and metastasis. Semin Radiat Oncol. 19:106–111. 2009. View Article : Google Scholar : PubMed/NCBI
13	Hoiseth SK and Stocker BA: Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature. 291:238–239. 1981. View Article : Google Scholar : PubMed/NCBI
14	Animal Research Advisory Committee, . Guidelines for Endpoints in Animal Study Proposals. http://oacu.od.nih.gov/ARAC/documents/ASP_Endpoints.pdfAccessed. February 1–2014
15	Chen G, Wei DP, Jia LJ, et al: Oral delivery of tumor-targeting Salmonella exhibits promising therapeutic efficacy and low toxicity. Cancer Sci. 100:2437–2443. 2009. View Article : Google Scholar : PubMed/NCBI
16	Liao D, Corle C, Seagroves TN and Johnson RS: Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res. 67:563–572. 2007. View Article : Google Scholar : PubMed/NCBI
17	Vaupel P: Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol. 14:198–206. 2004. View Article : Google Scholar : PubMed/NCBI
18	Brown J and Wilson W: Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 4:437–447. 2004. View Article : Google Scholar : PubMed/NCBI
19	Movsas B, Chapman JD, Hanlon AL, et al: Hypoxia in human prostate carcinoma: an Eppendorf PO2 study. Am J Clin Oncol. 24:458–461. 2001. View Article : Google Scholar : PubMed/NCBI
20	Maxwell PH, Pugh CW and Ratcliffe PJ: Activation of the HIF pathway in cancer. Curr Opin Genet Dev. 11:293–299. 2001. View Article : Google Scholar : PubMed/NCBI
21	Brown JM and Giaccia AJ: The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 58:1408–1416. 1998.PubMed/NCBI
22	Brown JM and Wilson WR: Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 4:437–447. 2004. View Article : Google Scholar : PubMed/NCBI
23	Jain RK and Forbes NS: Can engineered bacteria help control cancer? Proc Natl Acad Sci USA. 98:14748–14750. 2001. View Article : Google Scholar : PubMed/NCBI
24	Chen J, Yang B, Cheng X, et al: Salmonella-mediated tumor-targeting TRAIL gene therapy significantly suppresses melanoma growth in mouse model. Cancer Sci. 103:325–333. 2012. View Article : Google Scholar : PubMed/NCBI
25	Pawelek JM, Low KB and Bermudes D: Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res. 57:4537–4544. 1997.PubMed/NCBI
26	Rosenberg SA, Speiss PJ and Kleiner DE: Antitumor effects in mice of the intravenous injection of attenuated Salmonella typhimurium. J Immunother. 25:218–225. 2002. View Article : Google Scholar : PubMed/NCBI
27	Segre JA, Nemhauser JL, Taylor BA, et al: Positional cloning of the nude locus: genetic, physical, and transcription maps of the region and mutations in the mouse and rat. Genomics. 28:549–559. 1995. View Article : Google Scholar : PubMed/NCBI
28	Avogadri F, Martinoli C, Petrovska L, et al: Cancer immunotherapy based on killing of Salmonella-infected tumor cells. Cancer Res. 65:3920–3927. 2005. View Article : Google Scholar : PubMed/NCBI
29	Marincola FM, Wang E, Herlyn M, Seliger B and Ferrone S: Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol. 24:335–342. 2003. View Article : Google Scholar : PubMed/NCBI
30	Cerundolo V, Hermans IF and Salio M: Dendritic cells: a journey from laboratory to clinic. Nat Immunol. 5:7–10. 2004. View Article : Google Scholar : PubMed/NCBI
31	Finn OJ: Cancer vaccines: between the idea and the reality. Nat Rev Immunol. 3:630–641. 2003. View Article : Google Scholar : PubMed/NCBI
32	Iida N, Dzutsev A, Stewart CA, et al: Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 342:967–970. 2013. View Article : Google Scholar : PubMed/NCBI
33	Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, et al: Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med. 5:677–685. 1999. View Article : Google Scholar : PubMed/NCBI
34	Garcia-Lora A, Algarra I and Garrido F: MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol. 195:346–355. 2003. View Article : Google Scholar : PubMed/NCBI
35	Ribas A, Timmerman JM, Butterfield LH and Economou JS: Determinant spreading and tumor responses after peptide-based cancer immunotherapy. Trends Immunol. 58–61. 2003. View Article : Google Scholar : PubMed/NCBI